Whalesbook
Eris Lifesciences is acquiring the remaining 30% stake in its subsidiary Swiss Parenterals for ₹423.3 crore through a share swap. This move aims to achieve full operational control, cost efficiencies, and financial consolidation, making Swiss Parenterals a wholly owned subsidiary. The deal is expected to close by March 2026. Swiss Parenterals, a parenteral products manufacturer, reported significant turnover growth.